Bulbar impairment represents a hallmark feature of Amyotrophic Lateral Sclerosis (ALS) that
significantly impacts survival and quality of life. Speech and swallowing dysfunction are key …

Background: Amyotrophic Lateral Sclerosis (ALS) is a relentlessly progressive
neurodegenerative condition with limited therapeutic options at present. Survival from …

Abstract Objective: The ALSFRS-R is limited by multidimensionality, which originates from
the summation of various subscales. This prevents a direct comparison between patients …

Amyotrophic lateral sclerosis (ALS) encompasses a heterogeneous group of phenotypes
with different progression rates, varying degree of extra-motor involvement and divergent …

Identifying groups of patients with similar disease progression patterns is key to understand
disease heterogeneity, guide clinical decisions and improve patient care. In this paper, we …

Objective Amyotrophic lateral sclerosis (ALS) is still incurable. Although different therapies
can affect the health and survival of patients. Our aim is to evaluate the effect of umbilical …

Amyotrophic lateral sclerosis (ALS) is a rare, progressive multi-system neurodegenerative
disorder. Its clinical presentation varies considerably leading to delays in diagnosis, which …

Amyotrophic lateral sclerosis (ALS) is an inexorably progressive neurodegenerative
condition with no effective disease-modifying therapy at present. Given the striking clinical …

Abstract Background: Radicava®(edaravone), approved for the treatment of amyotrophic
lateral sclerosis (ALS) in 2017, may be administered intravenously at clinic sites, infusion …

Abstract Background Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease
whose spreading and progression mechanisms are still unclear. The ability to predict ALS …